United Kingdom Autoinjectors Market Size, Share & Trends Analysis Report By Type (Disposable autoinjectors, Reusable autoinjectors), By Application (Rheumatoid arthritis, Anaphylaxis, Multiple sclerosis, Others), By End-User (Home Care Settings, Hospitals and Clinics) and Forecasts, 2024-2032

Market Overview

The United Kingdom autoinjectors market size witnessed significant growth and is expected to grow at a CAGR of around 19.8% during the forecast period. (2022-2030).

Highlights

• Anaphylaxis dominates the market by therapy.
• Disposable dominates the market by type.
• Homecare dominates the market by end-user.

An autoinjector is a medical tool used to administer a certain amount of medication, usually by injection. It is made to be simple to use by the patient or caregiver. It often includes a pre-filled syringe, a needle, and a spring-loaded mechanism that releases the medication fast and easily with the push of a button. Common uses for autoinjectors include treating, among others, illnesses including allergies, arthritic, and multiple sclerosis. They can help lower the danger of unintentional needle stick injuries and are frequently utilized in emergency settings where quick drug administration is required.

Market Dynamics

United Kingdom Autoinjectors Market Drivers

Increasing Incidences of Anaphylactic Shock

The number of anaphylactic shock cases documented in the U.K. has noticeably increased. This increase can be ascribed to several things, such as increased allergies, environmental changes, and better reporting and knowledge of anaphylactic events. The U.K.'s National Health Service (NHS) has acknowledged the significance of immediately and successfully treating anaphylactic shock. As a result, there is a large demand for autoinjectors, particularly those that contain epinephrine (adrenaline). Epinephrine autoinjectors are frequently utilized as the first line of treatment to quickly treat symptoms of anaphylactic shock and avoid potentially fatal consequences.

The demand for autoinjectors has grown as a result of the rise in anaphylactic shock cases in the U.K. Pharmaceutical companies, like Mylan N.V. (now Viatris Inc.), the maker of the EpiPen, have been spurred by this trend to spend on R&D, ensuring the availability of cutting-edge autoinjector devices and enhancing patient outcomes.

United Kingdom Autoinjectors Market Restraints

Increasing Preference for Alternative Drug Delivery Modes

Technology and new drug delivery methods have expanded patient medicine alternatives. In specific therapeutic areas, inhalers, transdermal patches, and oral drugs have become popular. Asthma and COPD patients prefer inhalers. Symptoms are quickly relieved with portable, convenient, and exact dosing inhalers. Inhalers may be preferable to autoinjectors for respiratory disorders. The autoinjectors market faces competition from alternative drug delivery methods.

United Kingdom Autoinjectors Market Opportunities

Streamline Regulatory Guidelines

Medical devices and pharmaceutical items are heavily regulated in the U.K. by the Medicines and Healthcare Products Regulatory Agency (MHRA). Before these items may be advertised and disseminated, the FDA ensures they adhere to safety, quality, and efficacy requirements. Streamlined regulatory rules can lessen the compliance burden on autoinjector producers, allowing them to market their goods more quickly and effectively. This may result in more innovation, rivalry, and autoinjector options for patients and healthcare professionals. The U.K. government has worked to simplify regulatory procedures in recent years to promote expansion and innovation in the healthcare sector. For instance, the MHRA has implemented programs like the Innovation Passport, which gives medical devices—including autoinjectors—that exhibit innovation and satisfy certain requirements a faster road.

Regional Analysis

The U.K. autoinjectors market will expand at the quickest rate due to the rising prevalence of anaphylaxis and the rising number of adrenaline autoinjectors (AAI) prescriptions. According to a study by NCBI, the incidence rate of anaphylaxis in the United Kingdom has risen sharply since 2012. The rate at which AAI is prescribed for each child is likewise increasing. Consequently, the U.K. autoinjectors market is anticipated to expand significantly throughout the predicted timeframe.

Growth in both areas will be sparked by introducing cutting-edge drug delivery methods and devices and attractive reimbursement policies for key companies.

Compared to other European countries, the U.K. has been shown to use diabetes pens extensively. The World Health Organization estimates that 60 million individuals in the European Region have diabetes, with people over 25 having a higher disease prevalence. A low population seeking treatment coupled with social stigma in some areas, poor awareness, and relatively limited access to healthcare facilities, particularly in developing countries, are a few obstacles that restrict the region's potential for growth.

Segmental Analysis

The United Kingdom autoinjectors market is segmented based on therapy, type, and end-user.

The market is further segmented by therapy into Anaphylaxis, Rheumatoid Arthritis, Psoriasis, migraines, Cardiovascular-diseases, and others.

The Anaphylaxis segment dominates the market and is expected to grow at a CAGR of 19.4% during the forecast period.

The market is further segmented by type into Disposable, Reusable.

Disposable dominated the market and is expected to register a CAGR of 19.2% over the forecast period.

The market is further segmented by end-user into Hospitals and clinics, home care, and others.

The home care segment dominates the market and is expected to grow at a CAGR of 20.4% during the forecast period.

Recent Developments

• May 2023- B.D. (Becton, Dickinson, and Company), a leading global medical technology company launched a new cell sorting instrument with two breakthrough technologies that allow researchers to discover more cell information than was previously possible in flow cytometry experiments.
• April 2023- Nutriband Inc. and Kindeva Drug Delivery ("Kindeva") selected the target AVERSATM formulation for commercial scale manufacturing process development for the Company's patented lead product, AVERSATM Fentanyl, an abuse-deterrent fentanyl transdermal system.